Please try another search
J. B. Chemicals & Pharmaceuticals Limited reported earnings results for the fourth quarter ended March 31, 2024. For the fourth quarter, the company reported sales was INR 8,617.3 million compared to INR 7,623.2 million a year ago. Revenue was INR 8,783.6 million compared to INR 7,669 million a year ago. Net income was INR 1,261.6 million compared to INR 876.3 million a year ago. Basic earnings per share from continuing operations was INR 8.22 compared to INR 5.67 a year ago. Diluted earnings per share from continuing operations was INR 8.06 compared to INR 5.6 a year ago.
Period Ending: | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 |
---|---|---|---|---|
Total Revenue | 8783.6 | 8445.1 | 8817.4 | 8962 |
Gross Profit | 5780.8 | 5708.8 | 5835.7 | 5862.3 |
Operating Income | 1740.1 | 1890.9 | 2113.7 | 2007.3 |
Net Income | 1261.6 | 1335.7 | 1505.9 | 1423.2 |
Period Ending: | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 |
---|---|---|---|---|
Total Assets | 37992 | |||
Total Liabilities | 10708 | 10824.9 | ||
Total Equity | 27167.1 | 27167.1 | 24803.52 |
Period Ending: | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | ||||
Cash From Investing Activities | ||||
Cash From Financing Activities | ||||
Net Change in Cash |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review